» Articles » PMID: 39257717

The Changing Scenario of Drug Discovery Using AI to Deep Learning: Recent Advancement, Success Stories, Collaborations, and Challenges

Overview
Publisher Cell Press
Date 2024 Sep 11
PMID 39257717
Authors
Affiliations
Soon will be listed here.
Abstract

Due to the transformation of artificial intelligence (AI) tools and technologies, AI-driven drug discovery has come to the forefront. It reduces the time and expenditure. Due to these advantages, pharmaceutical industries are concentrating on AI-driven drug discovery. Several drug molecules have been discovered using AI-based techniques and tools, and several newly AI-discovered drug molecules have already entered clinical trials. In this review, we first present the data and their resources in the pharmaceutical sector for AI-driven drug discovery and illustrated some significant algorithms or techniques used for AI and ML which are used in this field. We gave an overview of the deep neural network (NN) models and compared them with artificial NNs. Then, we illustrate the recent advancement of the landscape of drug discovery using AI to deep learning, such as the identification of drug targets, prediction of their structure, estimation of drug-target interaction, estimation of drug-target binding affinity, design of drug, prediction of drug toxicity, estimation of absorption, distribution, metabolism, excretion, toxicity; and estimation of drug-drug interaction. Moreover, we highlighted the success stories of AI-driven drug discovery and discussed several collaboration and the challenges in this area. The discussions in the article will enrich the pharmaceutical industry.

Citing Articles

Integrating natural product research laboratory with artificial intelligence: Advancements and breakthroughs in traditional medicine.

Yang J, Tsai S, Hsu Y, Bau D, Tsai C, Chang W Biomedicine (Taipei). 2025; 14(4):1-14.

PMID: 39777110 PMC: 11703400. DOI: 10.37796/2211-8039.1475.


From Bench to Bedside: Translating Cellular Rejuvenation Therapies into Clinical Applications.

Saliev T, Singh P Cells. 2025; 13(24.

PMID: 39768144 PMC: 11674796. DOI: 10.3390/cells13242052.

References
1.
Ye L, Ngan D, Xu T, Liu Z, Zhao J, Sakamuru S . Prediction of drug-induced liver injury and cardiotoxicity using chemical structure and in vitro assay data. Toxicol Appl Pharmacol. 2022; 454:116250. PMC: 9561045. DOI: 10.1016/j.taap.2022.116250. View

2.
Ozturk H, Ozgur A, Ozkirimli E . DeepDTA: deep drug-target binding affinity prediction. Bioinformatics. 2018; 34(17):i821-i829. PMC: 6129291. DOI: 10.1093/bioinformatics/bty593. View

3.
Liu S, Zhang Y, Cui Y, Qiu Y, Deng Y, Zhang Z . Enhancing Drug-Drug Interaction Prediction Using Deep Attention Neural Networks. IEEE/ACM Trans Comput Biol Bioinform. 2022; 20(2):976-985. DOI: 10.1109/TCBB.2022.3172421. View

4.
Richard A, Judson R, Houck K, Grulke C, Volarath P, Thillainadarajah I . ToxCast Chemical Landscape: Paving the Road to 21st Century Toxicology. Chem Res Toxicol. 2016; 29(8):1225-51. DOI: 10.1021/acs.chemrestox.6b00135. View

5.
Liu X, Ye K, van Vlijmen H, Emmerich M, IJzerman A, van Westen G . DrugEx v2: de novo design of drug molecules by Pareto-based multi-objective reinforcement learning in polypharmacology. J Cheminform. 2021; 13(1):85. PMC: 8588612. DOI: 10.1186/s13321-021-00561-9. View